Q2 EPS Forecast for Enliven Therapeutics Boosted by Analyst

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for Enliven Therapeutics in a report issued on Wednesday, July 2nd. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.57) per share for the quarter, up from their previous estimate of ($0.60). HC Wainwright has a "Buy" rating and a $48.00 price target on the stock. The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Enliven Therapeutics' Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.14) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.42) EPS.

Several other analysts also recently issued reports on ELVN. Jones Trading decreased their price target on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Robert W. Baird increased their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Finally, The Goldman Sachs Group began coverage on Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of "Buy" and a consensus target price of $41.20.

Enliven Therapeutics Stock Performance

ELVN opened at $20.68 on Friday. The company has a market cap of $1.01 billion, a PE ratio of -10.77 and a beta of 0.83. The stock has a 50-day moving average of $19.49 and a 200-day moving average of $20.40. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06).

Insider Transactions at Enliven Therapeutics

In related news, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total transaction of $277,250.00. Following the completion of the sale, the chief executive officer directly owned 952,892 shares of the company's stock, valued at $21,135,144.56. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.34, for a total value of $135,606.78. Following the completion of the sale, the chief operating officer owned 303,309 shares of the company's stock, valued at $6,169,305.06. This trade represents a 2.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 100,111 shares of company stock valued at $1,939,549 over the last quarter. Corporate insiders own 25.90% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently modified their holdings of the business. Ameriprise Financial Inc. acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth about $789,000. Millennium Management LLC boosted its position in Enliven Therapeutics by 108.6% during the fourth quarter. Millennium Management LLC now owns 50,804 shares of the company's stock valued at $1,143,000 after purchasing an additional 26,449 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Enliven Therapeutics by 67.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after purchasing an additional 17,546 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Enliven Therapeutics by 4.9% in the first quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock valued at $1,033,000 after buying an additional 2,466 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Enliven Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock valued at $5,892,000 after buying an additional 6,611 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.